| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2023: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2022: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2021: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we aimed to develop a novel and effective adoptive designer T cell therapy utilizing novel retrovirus vector with siRNA technology based on the previous development of "stealth T cell" technology.
(1) We successfully created CD47 over-expressing human designer T cells using retrovirus vector. (2)Utilizing GPX4 over-expressing human designer T cells, we could exhibit the synergistic anti-tumor effect of ferroptosis inducer and designer T cell therapy that overcome tumor heterogeneity.
|
